|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||312.497 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
JWH-133 (Dimethylbutyl-deoxy-Delta-8-THC) is a potent selective CB2 receptor agonist with a Ki of 3.4nM and selectivity of around 200x for CB2 over CB1 receptors. It was discovered by and named after, John W. Huffman.
It's important to note that JWH-133 has been confused with other analogs of Delta-8-THC in professionally published peer-reviewed literature. Including being confused with Dimethylpentyl-Delta-8-THC as well as Dimethylbutyl-Delta-8-THC. Including confusing the chemical name with Dimethylbutyl-Delta-8-THC itself. Including confusing it with the Delta-9 isomer Including using the structural image of Dimethylbutyl-Delta-8-THC instead of Dimethylbutyl-deoxy-Delta-8-THC.
It's important to note that 3-(1',1'-Dimethylbutyl)-1-deoxy-delta-8-THC is a selective CB2 agonist, binding 677nM at Cb1 and 3.4nM at CB2 while 3-(1',1'-Dimethylbutyl)-delta-8-THC itself binds 65nM at CB1. Structurally the only difference between JWH-133 and dimethylbutyl-D8-THC is that JWH-133 lacks the hydroxy group seen on dimethylbutyl-D8-THCs phenol structure (the C1 position of the A ring), turning this group into a phenyl (JWH-133) instead of phenol. It's generally accepted that removing the hydroxy group from the phenol structure of any classical cannabinoid benzoypran (such as THC) results in dramatically less CB1 activity and heightened CB2 activity.
JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's disease, in addition to preventing cognitive impairment and loss of neuronal markers. This anti-inflammatory action is induced through agonist action at the CB2 receptor, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids at this receptor completely abolish neurotoxicity related to microglia activation in rat models.
JWH-133 is not specifically listed in the United States controlled substance act but may be considered an analog of THC if sold for human consumption under the Federal Analogue Act.
- Bow EW, Rimoldi JM (28 June 2016). "The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation". Perspectives in Medicinal Chemistry. 8: 17–39. doi:10.4137/PMC.S32171. PMC 4927043. PMID 27398024.
- Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR (December 1999). "3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor". Bioorganic & Medicinal Chemistry. 7 (12): 2905–2914. doi:10.1016/S0968-0896(99)00219-9. PMID 10658595.
- Huffman JW, Miller JR, Liddle J, Yu S, Thomas BF, Wiley JL, Martin BR (April 2003). "Structure-activity relationships for 1',1'-dimethylalkyl-Delta8-tetrahydrocannabinols". Bioorganic & Medicinal Chemistry. 11 (7): 1397–1410. doi:10.1016/s0968-0896(02)00649-1. PMID 12628666.
- Caffarel MM, Andradas C, Mira E, Pérez-Gómez E, Cerutti C, Moreno-Bueno G, et al. (July 2010). "Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition". Molecular Cancer. 9 (1): 196. doi:10.1186/1476-4598-9-196. PMC 2917429. PMID 20649976.
- "Marijuana Compound Halts Breast Cancer Tumor Growth". NORML. August 5, 2010.
- "Federal Register :: Request Access".
- Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML (February 2005). "Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation". The Journal of Neuroscience. 25 (8): 1904–1913. doi:10.1523/JNEUROSCI.4540-04.2005. PMC 6726060. PMID 15728830.